Literature DB >> 8282345

Role of the lipoxygenase pathway in angiotensin II-induced vascular smooth muscle cell hypertrophy.

R Natarajan1, N Gonzales, L Lanting, J Nadler.   

Abstract

The 12-lipoxygenase pathway is a key mediator of angiotensin II (Ang II)-induced effects in the adrenal cortex. We also recently demonstrated that Ang II increases 12- and 15-lipoxygenase product levels in vascular smooth muscle cells. However, the relation between lipoxygenase activation and Ang II-induced vascular smooth muscle cell hypertrophy is not known. We studied the effects of Ang II and 12-lipoxygenase products on both total cell protein content and the levels of the matrix protein fibronectin in quiescent porcine aortic smooth muscle cells. Ang II-induced increases in cellular protein content were attenuated by the specific 12-lipoxygenase inhibitor baicalein; in contrast, the cyclooxygenase inhibitor ibuprofen had no effect. Direct addition of the 12-lipoxygenase product 12-S-hydroxyeicosatetraenoic acid increased total cell protein content. We have recently shown that porcine vascular smooth muscle cell growth is potentiated in high glucose (25 mmol/L) culture conditions. We observed that both Ang II and 12-S-hydroxyeicosatetraenoic acid induced a greater increase in protein content in cells cultured for two passages in high glucose. Furthermore, Ang II and 12-S-hydroxyeicosatetraenoic acid also markedly increased fibronectin levels in cells cultured in high glucose. These results suggest that 12-lipoxygenase activation plays a key role in Ang II-induced vascular smooth muscle cell hypertrophy. Furthermore, both Ang II and lipoxygenase effects are enhanced in cells cultured under hyperglycemic conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282345     DOI: 10.1161/01.hyp.23.1_suppl.i142

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  The effects of leukocyte-type 12/15-lipoxygenase on Id3-mediated vascular smooth muscle cell growth.

Authors:  Angela M Taylor; Ross Hanchett; Rama Natarajan; Catherine C Hedrick; Scott Forrest; Jerry L Nadler; Coleen A McNamara
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07-21       Impact factor: 8.311

2.  Use of a hammerhead ribozyme with cationic liposomes to reduce leukocyte type 12-lipoxygenase expression in vascular smooth muscle.

Authors:  J L Gu; J Nadler; J Rossi
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

Review 3.  Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.

Authors:  John D Imig; Md Abdul Hye Khan
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

4.  Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation.

Authors:  Fariborz A Yaghini; Chi Young Song; Eduard N Lavrentyev; Hafiz U B Ghafoor; Xiao R Fang; Anne M Estes; William B Campbell; Kafait U Malik
Journal:  Hypertension       Date:  2010-05-03       Impact factor: 10.190

5.  Small RNA sequencing reveals microRNAs that modulate angiotensin II effects in vascular smooth muscle cells.

Authors:  Wen Jin; Marpadga A Reddy; Zhuo Chen; Sumanth Putta; Linda Lanting; Mitsuo Kato; Jung Tak Park; Manasa Chandra; Charles Wang; Rajendra K Tangirala; Rama Natarajan
Journal:  J Biol Chem       Date:  2012-03-19       Impact factor: 5.157

6.  Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice.

Authors:  Peter B Anning; Barbara Coles; Alexandra Bermudez-Fajardo; Patricia E M Martin; Bruce S Levison; Stanley L Hazen; Colin D Funk; Hartmut Kühn; Valerie B O'Donnell
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

7.  Baicalein attenuates intimal hyperplasia after rat carotid balloon injury through arresting cell-cycle progression and inhibiting ERK, Akt, and NF-kappaB activity in vascular smooth-muscle cells.

Authors:  Chieh-Yu Peng; Shiow-Lin Pan; Ying-Wen Huang; Jih-Hwa Guh; Ya-Ling Chang; Che-Ming Teng
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-29       Impact factor: 3.000

8.  Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes.

Authors:  Hang Yuan; Linda Lanting; Zhong-Gao Xu; Shu-Lian Li; Piotr Swiderski; Sumanth Putta; Mahesh Jonnalagadda; Mitsuo Kato; Rama Natarajan
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-18

9.  Role of Src tyrosine kinase in the atherogenic effects of the 12/15-lipoxygenase pathway in vascular smooth muscle cells.

Authors:  Marpadga A Reddy; Saurabh Sahar; Louisa M Villeneuve; Linda Lanting; Rama Natarajan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-12-18       Impact factor: 8.311

10.  Products of 12/15-lipoxygenase upregulate the angiotensin II receptor.

Authors:  Zhong-Gao Xu; Hang Yuan; Linda Lanting; Shu-Lian Li; Mei Wang; Narkunaraja Shanmugam; Mitsuo Kato; Sharon G Adler; Marpadga A Reddy; Rama Natarajan
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.